Humana stock has delivered a strong 69.8% return over the past year, and with the broader valuation checks sending a mixed signal rather than a clear bargain or obvious excess, investors are left weighing how much upside is already reflected in the current price.

• Over the last 1 year, Humana is up 69.8%, which puts recent buyers in a comfortable position but also raises questions about how much good news is already in the share price.
• The upcoming expansion of Humana's Medicaid presence in Illinois through the HealthChoice program can support longer term revenue expectations, while scrutiny of its Medicare Advantage outlook and business mix remains a key risk for how the market prices the stock.
• With a valuation score of 3 out of 6, Humana screens as roughly in the middle of the pack, pointing to a mixed picture rather than a clear bargain or clear overvaluation.

The issue now is whether Humana's recent rerating leaves enough room for further returns without stretching the valuation too far.

Does Humana Look Fairly Valued on Earnings?

The P/E ratio is a useful yardstick for Humana because it links what you pay for the stock directly to the earnings the business is generating today. Humana currently trades at about 42.1x earnings, which sits above the broader Healthcare sector average of 25.0x and also above the peer group average of 36.9x. On a simple comparison, that points to investors paying a higher price for each dollar of Humana's earnings than for many other healthcare stocks.

However, the Fair P/E Ratio, which incorporates factors such as Humana's margins, risk profile and scale, sits at 44.6x. Against that yardstick, the current 42.1x multiple is slightly below what this framework would imply. Despite the recent positive attention around Humana's selection for the Illinois HealthChoice Medicaid program, the P/E still lines up reasonably closely with this more tailored benchmark rather than signaling an extreme premium.

Overall, Humana's stock appears to be trading at roughly a fair level based on its current P/E multiple.

The Humana Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Humana pick up where the P/E discussion leaves off by spelling out which paths for Humana's growth, margins and earnings would need to play out for the stock to be worth meaningfully more or less than it is today on Simply Wall St's Community page. Rather than relying on a single ratio or model output, they describe the future that number depends on so you can see, over time, whether those assumptions are actually taking shape.

Community views on Humana sit far apart, with one side focused on margin recovery potential and the other on tightening Medicare scrutiny.

Bull case: 10% undervalued

"Ongoing expansion and maturation of the CenterWell platform (primary care, home health, and pharmacy) is expected to boost per-member-per-month payments and operating leverage as new clinics move through the J-curve, supporting both revenue and long-term earnings growth..."

Bear case: 86% overvalued

"Across the industry, regulators are sharpening their focus on how health plans document risk adjustment data and apply prior authorization standards..."

Do you think there's more to the story for Humana? Head over to our Community to see what others are saying!

The Bottom Line

Humana now sits in a zone where the market-multiple view points to about_right pricing rather than a clear discount or premium. The current P/E is not screamingly cheap, so future returns are likely to lean more on how earnings and margins evolve than on further multiple expansion. For you as an investor, the key question is whether Humana can sustain and monetise its health plan and CenterWell ambitions while managing tighter Medicare oversight, because that earnings path is what will decide whether today’s valuation proves cautious or optimistic.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.